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Abstract
Porcine pleuropneumonia caused by Actinobacillus pleuropneumoniae accounts for serious economic losses in the
pig farming industry worldwide. We examined here the immunogenicity and protective efficacy of the
recombinant type IV fimbrial subunit protein ApfA as a single antigen vaccine against pleuropneumonia, or as a
component of a multi-antigen preparation comprising five other recombinant antigens derived from key virulence
factors of A. pleuropneumoniae (ApxIA, ApxIIA, ApxIIIA, ApxIVA and TbpB). Immunization of pigs with recombinant
ApfA alone induced high levels of specific serum antibodies and provided partial protection against challenge with
the heterologous A. pleuropneumoniae serotype 9 strain. This protection was higher than that engendered by
vaccination with rApxIVA or rTbpB alone and similar to that observed after immunization with the tri-antigen
combination of rApxIA, rApxIIA and rApxIIIA. In addition, rApfA improved the vaccination potential of the penta-
antigen mixture of rApxIA, rApxIIA, rApxIIIA, rApxIVA and rTbpB proteins, where the hexa-antigen vaccine
containing rApfA conferred a high level of protection on pigs against the disease. Moreover, when rApfA was used
for vaccination alone or in combination with other antigens, such immunization reduced the number of pigs
colonized with the challenge strain. These results indicate that ApfA could be a valuable component of an efficient
subunit vaccine for the prevention of porcine pleuropneumonia.
Introduction
Actinobacillus pleuropneumoniae, the etiological agent of
porcine pleuropneumonia, is a Gram-negative bacterium
colonizing the porcine respiratory tract [1-3]. Pleuropneu-
monia is a severe contagious and economically significant
disease. It can range from acute to chronic, depending on
host age, immune status, the bacterial strain causing the
infection, or the infective dose [4-6]. The acute stage is
characterized by a haemorrhagic necrotizing pneumonia
and fibrinous pleuritis and may progress rapidly to death
[7,8]. In the chronic stage, localized lung lesions and adhe-
sive pleuritis can be observed and chronically infected
animals can become a source of infection for the whole
non-infected herd [1,2,9].
To control porcine pleuropneumonia, vaccination is
useful [10,11], but development of efficient vaccines
against the disease appears difficult due to the existence
and diversity of 15 serotypes of A. pleuropneumoniae that
are differentiated on the basis of surface polysaccharide
antigens [12-14]. The first vaccines against A. pleuropneu-
moniae infection comprised formalin-treated or heat-inac-
tivated bacteria. These whole-cell bacterin vaccines reduce
mortality after challenge with the homologous serotypes
of A. pleuropneumoniae, but usually do not confer efficient
protection against infection with heterologous serotypes
[15-17]. The limited protection observed with bacterins
might be explained by (i) the absence of secreted immuno-
g e n i cp r o t e i n s ,s u c ha st h eA p x At o x i n st h a ta r et h ek e y
virulence factors of A. pleuropneumoniae, (ii) the altera-
tion of antigenic potency of certain bacterial antigens due
to inactivation treatment, or (iii) the absence of immuno-
genic antigens that are expressed only within the host
[11,18-22]. Indeed, pigs surviving natural or experimental
infection with A. pleuropneumoniae were found to be com-
pletely protected against homologous serotypes and gener-
ally also against heterologous serotype infections [16,23,24].
To overcome the drawbacks of bacterins, live attenuated
vaccines that reflect natural A. pleuropneumoniae infection
and allow the in-vivo production of immunogenic antigens
were developed, comprising temperature-sensitive, strepto-
mycin-dependent or metabolic mutants, or mutants having
deleted or inactivated genes for key virulence factors
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confer a high-level cross-protection in contrast to whole-
cell bacterin vaccines [30,35,36]. Despite many promising
results, the use of live bacteria brings numerous safety
drawbacks that could be eliminated by the development of
a highly efficient subunit vaccine. Among the valuable com-
ponents of different subunit vaccines, the key virulence fac-
tors of A. pleuropneumoniae, such as the ApxA exotoxins,
the outer membrane proteins, or iron-acquisition factors,
were tested, respectively [11].
A. pleuropneumoniae secretes three different ApxA exo-
toxins (ApxIA, ApxIIA, and ApxIIIA), which are members
of the RTX (Repeat in ToXin) family [3,37-42]. ApxIA
shows strong hemolytic activity, while ApxIIA exhibits
weaker hemolytic activity [43,44]. Both are cytotoxic and
active on a broad range of cells of different types and spe-
cies [45]. ApxIIIA is nonhemolytic, but it is strongly cyto-
toxic and targets mainly porcine alveolar macrophages
and neutrophils [44,46]. The ApxA exotoxins are thought
to be of particular importance as antigens for inducing
protective immunity against pleuropneumonia and have
been included in a broad range of tested subunit vaccines
[21,47-49]. A fourth secreted RTX protein of A. pleurop-
neumoniae, ApxIVA, was described and its biologic activ-
ity remains unknown [50]. ApxIVA appears to be
produced in vivo but not under in vitro conditions [19,50].
Recently, the contribution of recombinant ApxIVA to the
protective efficacy of a subunit vaccine against A. pleurop-
neumoniae challenge was demonstrated [49].
To survive in the iron-depleted environment of the host,
A. pleuropneumoniae produces the surface proteins, TbpA
and TbpB (transferrin binding proteins), that enable the
pathogen to utilize porcine transferrin as a source of iron
[51]. Both transferrin binding proteins are key virulence
factors of A. pleuropneumoniae [52]. It has been shown
that pigs immunized with recombinant TbpB are less sus-
ceptible to the disease after experimental homologous
challenge with A. pleuropneumoniae serotype 7 [53].
Since each of the A. pleuropneumoniae proteins alone
offers only a partial protection against porcine pleurop-
neumonia, current commercially available or newly tested
vaccines consist of combinations of several bacterial anti-
gens [21,47-49,53]. These subunit vaccines are effective
at preventing acute disease, but do not sufficiently pro-
tect against colonization and are not widely cross-protec-
tive [33,47]. Therefore, further A. pleuropneumoniae
outer membrane and/or secreted proteins are screened
and tested as candidates for inclusion into next genera-
tion vaccines [54]. Among the promising antigens to be
included in a subunit vaccine against porcine pleurop-
neumonia is the type IV fimbrial subunit protein. Type
IV fimbriae (pili) are typically composed of thousands of
subunit proteins polymerized into a fiber that protrudes
from the bacterial cell surface [55]. Fimbriae are, indeed,
known to play an important role in the pathogenesis of
Gram-negative bacteria such as Moraxella catarrhalis,
Neisseria meningitidis, N. gonorrhoeae, Haemophilus
influenzae, enteropathogenic Escherichia coli or Pseudo-
monas aeruginosa and are involved in adherence and
colonization, twitching motility, biofilm formation, pro-
tein export and DNA uptake [56-63]. Type IV fimbriae
were also isolated from A. pleuropneumoniae and a 15.9-
kDa ApfA protein was identified as the type IV fimbrial
subunit protein [55]. The apfA gene was found to be pre-
sent in 12 representative A. pleuropneumoniae serotype
strains and exhibited greater than 98% identity on DNA
level with the predicted amino acid sequences being
100% identical [64]. Moreover, all typical fimbrial biogen-
esis genes were identified in A. pleuropneumoniae and
appear to form a type IV fimbrial operon with apfA [18].
This is present in a single copy in the A. pleuropneumo-
niae genome and was found to be expressed in vivo, but
not in vitro [18]. The single copy and high conservation
of the apfA gene, the surface location of the ApfA protein
and its putative role in adherence, colonization and other
important biological functions, make ApfA a particularly
attractive target for vaccine development.
Here, we tested the immunogenicity and protective
potential of recombinant ApfA against porcine pleurop-
neumonia, either in a single antigen vaccine, or as a com-
ponent of a multi-antigen preparation, including five other
purified recombinant antigens derived from key virulence
factors of A. pleuropneumoniae.
Materials and methods
Bacterial strains and growth conditions
The E. coli K12 strain, XL1-Blue (Stratagene, La Jolla,
USA), was used throughout this work for DNA manipu-
lations and was grown in Luria-Bertani (LB) medium
supplemented with 60 μg/mL of kanamycin. The E. coli
BL21(lDE3) strain (Invitrogene, Carlsbad, USA) was
used for expression of recombinant proteins and was
g r o w na t3 7 ° Ci nL Bm e d i u mc o n t a i n i n g6 0μg/mL of
kanamycin.
A. pleuropneumoniae serotypes 1, 2, 3 and 7 were used
for isolation of genomic DNA and A. pleuropneumoniae
serotype 9 strain was used for challenge experiments.
A. pleuropneumoniae serotype 7 strain was obtained from
the Veterinary Research Institute, Czech Republic - Col-
lection of animal pathogenic microorganisms (CAPM
3800 serovar 7, strain: WF 83, S. Rosendal, Canada, source:
pig/lung (pleuropneumonia)). All other serotypes of
A. pleuropneumoniae were isolated in the Moravske Prusy
agricultural co-operative (Czech Republic) from the lungs
of pigs with respiratory infection (after necropsy). It was
verified by PCR-cloning and DNA sequencing that the ser-
otype 9 strain used for challenge experiments harbored a
fully conserved apfA gene allele.
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(Lab M, Bury, UK) supplemented with 10% NAD (Sigma-
Aldrich, St. Louis, USA) for 24 h at 37°C in 5% CO2 and
then inoculated into the liquid culture (Supplemented
Columbia broth (BBL Microbiology Systems, Cockeysville,
USA)) supplemented with 1% IsoVitaleX (BBL Microbiol-
ogy Systems, Cockeysville, USA) and 10 μg/mL of NAD,
grown for 6 h and harvested by centrifugation at 4 500 × g
for 15 min.
Isolation and cloning of genes encoding ApfA, ApxA and
TbpB proteins
The A. pleuropneumoniae genomic DNA was isolated from
serotypes 1, 2, 3 and 7 using phenol-chloroform extraction
[65] and the apfA, apxIA, apxIIA, apxIIIA, apxIVA and
tbpB genes were amplified by polymerase chain reaction
(PCR) (Table 1). Reaction mixtures (70 μL) contained 100
ng of genomic DNA, 2 μM of each oligonucleotide primer,
100 mM KCl, 20 mM Tris-HCl (pH 8.3), 7.5 mM MgCl2,
1 mM DTT, 200 μg/mL BSA, 140 μM of each dNTP and
1 unit of Phusion DNA polymerase (Finnzymes, Espoo,
Finland). Reaction mixtures were pre-heated to 98°C for
30 s and subjected to 30 cycles of 98°C for 10 s, 52°C for
30 s, and 72°C for 3 min using a PCR Sprint instrument
(ThermoHybaid, Middlesex, UK). Specific primer pairs for
PCR amplification were designed based on the published
sequences of the apfA, apxIA, apxIIA, apxIIIA, apxIVA and
tbpB genes (Table 1) [37,66,67]. To facilitate cloning, the
primers were designed to produce a PCR product with a
restriction site for the Sal I enzyme at the 5’-end and for
Not Ia tt h e3 ’-end, respectively (Table 1). PCR products
were isolated from agarose gel, digested with the Sal Ia n d
Not I restriction enzymes and fused in frame with the
sequence for 6 × His tag at the 5’- and 3’-ends by cloning
into the Sal Ia n dNot I sites of the modified pET28b_Nco-
Sal vector. This construct was prepared by ligation of Nco
I-Sal I digested pET28b (Novagen, Madison, USA) with a
double-stranded adapter (5’-CATGCATCATCATCAT-
CATCATCATAG-3’ and 5’-TCGACTATGATGATGAT-
GATGATGATG-3’). The set of expression vectors,
pET28b-apfA, pET28b-apxIA, pET28b-apxIIA, pET28b-
apxIIIA,p E T 2 8 b - apxIVA and pET28b-tbpB,w a sv e r i f i e d
by restriction analysis and DNA sequencing.
Protein production and purification
All recombinant proteins were produced in E. coli strain
BL21(lDE3) transformed with the appropriate plasmid.
Exponential 500 mL cultures grown with shaking at 37°C
in LB medium supplemented with 60 μg/mL of kanamycin
were induced at OD600 =0 . 6-0 . 8w i t h1m MI P T Ga n d
grown for an additional 4 h. The cells were harvested by
centrifugation, washed twice with 50 mM Tris-HCl (pH
8.0), 150 mM NaCl (TN buffer) and disrupted by sonica-
tion at 4°C. The extracts were cleared at 20 000 × g for
20 min, supernatants were discarded and pellets were
solubilized with 50 mM Tris-HCl (pH 8.0), 8 M urea and
300 mM NaCl (TUN buffer) and centrifuged at 20 000 × g
for additional 20 min. The obtained urea extracts were
loaded on a Ni-NTA agarose column (Qiagen, Valencia,
USA) equilibrated with the TUN buffer. Washing was per-
formed with equilibration buffer and recombinant proteins
were eluted with TUN buffer supplemented with 250 mM
imidazole. To remove the imidazole from the samples, the
most concentrated fractions were loaded on Sephadex G-
25 (Sigma-Aldrich, St. Louis, USA) and transferred into
the TUN buffer.
DNA manipulations and recombinant protein analysis
SDS polyacrylamide gel electrophoresis (SDS-PAGE),
Western blot analysis, determination of protein concen-
trations and in vitro DNA manipulations were per-
formed according to standard protocols [65].
Table 1 PCR primer pairs, origin and features of apfA, apxA and tbpB genes and corresponding proteins
Gene
1 A. pleuropneumoniae
serotype
PCR primer pair (5’ ® 3’)
2 Gene length
(bps)
Protein MW
(kDa)
3
apfA 7C C GTCGACATGTCATATAACAGTTATAC
CCGCGGCCGCATTTGATGCGCAGAAATTT
342 14
apxIA 1G G GTCGACACGCTAACTCTCAGCTCGATA
GGGCGGCCGCAGCTGCTTGTGCTAAAGAA
3069 113
apxIIA 7C C GTCGACACTCAAAAATCACTTTGTCATCA
CCGCGGCCGCAGCGGCTCTAGCTAATTG
2871 105
apxIIIA 2G G GTCGACACAGTACTTGGTCAAGCATGTT
GGGCGGCCGCAGCTGCTCTAGCTAGGTTA
3159 115
apxIVA 3C C GTCGACACACAAAATTAACTATGCAAGA
CCGCGGCCGCTAAAGCAGCTGTTAAGCTATT
5418 205
tbpB 7C C GTCGACACTCTGGCGGAAAAGGAAGTT
CCGCGGCCGCTTTTTTTACTTGTTGTTTTGCA
1644 60
1Sequences of genes were acquired from GenBank (apfA, AY235719.1; apxIA, AF240779; apxIIA, CP001091; apxIIIA, L12145; apxIVA, AF030511; tbpB, U16017).
2All oligonucleotides were synthesized by Generi Biotech, Hradec Kralove, Czech Republic. First oligonucleotide represents forward PCR primer, second reverse
PCR primer. Sal I and Not I recognition sites are marked in bold and underlined.
3The approximate protein molecular weight was calculated using the Compute pI/Mw tool (ExPASy).
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experiments
A. pleuropneumoniae serotype 9 strain was grown to
OD600 = 0.6, culture was centrifuged at 4 500 × g for
15 min and resuspended in sterile PBS (phosphate-buf-
fered saline, pH 7.4). The suspension was plated in tripli-
cate in 10-fold serial dilutions onto Columbia agar
supplemented with 10% NAD and grown for 24 h at 37°C
in 5% CO2 for the exact estimation of the number of col-
ony-forming units (CFU). The bacteria used for challenge
experiments were tested by Western blot for the produc-
tion of ApxIA and ApxIIA toxins that are known to be of
major importance for the full virulence of A. pleuropneu-
moniae . The challenge suspension was administered to
experimental animals using an intranasal probe.
Experimental animals
For the immunization and challenge experiments, 8-week
old piglets (Agricultural Co-operative, Tesnovice, Czech
Republic) of both genders, cross-breeds of Czech White
and Landrace, weighting 21-24 kg, were used. All piglets
were tested prior to vaccination for the absence of serum
antibodies against A. pleuropneumoniae (Chekit APP-
ApxIV, IDEXX Laboratories, Westbrook, USA), Pasteur-
ella multocida (PMT ELISA Kit, DakoCytomation,
Glostrup, Denmark), Mycoplasma hyopneumoniae (Herd-
Chek M. hyo, IDEXX), Salmonella spp. (HerdChek Swine
Salmonella, IDEXX), porcine reproductive and respiratory
syndrome virus (IDEXX PRRS X3, IDEXX), swine influ-
enza virus (CIVTEST Suis Influenza, Hipra Laboratories,
Gerona, Spain) and pseudorabies virus (HerdChek Anti-
PRV gB, IDEXX), respectively. None of the piglets showed
disease signs before or at the time of challenge. Handling
with animals was performed according to the national leg-
islation on animal welfare and in line with internal guide-
lines of Bioveta, a. s. (SOPs of Bioveta and the Guidelines
for the Care and Use of Laboratory Animals, the Act of
the Czech National Assembly, Collection of laws No. 149/
2004, inclusive of the amendments, on the Protection of
Animals against Cruelty, and Public Notice of the Ministry
of Agriculture of the Czech Republic, Collection of laws
No. 207/2004, on keeping and exploitation of experimen-
tal animals).
Determination of A. pleuropneumoniae challenge
dose in pigs
The challenge dose for the intranasal infection, eliciting
overt signs of severe porcine pleuropneumonia and caus-
ing mortality in 50% of animals (LD50), was determined
for a local A. pleuropneumoniae serotype 9 strain. Three
groups of four pigs were inoculated intranasally with 3 ×
10
6,1×1 0
7 and 2 × 10
8 CFU (each 5 mL dose was split
into two 2.5 mL aliquots and applied to both nostrils) of
bacteria and the pigs were monitored daily for 4 days for
signs of morbidity and mortality rate. Two out of four
challenged pigs died within 24 hours from challenge with
the dose of 2 × 10
8 CFU, which was used further as the
challenge dose in tests of vaccine potency.
Immunizations and challenge experiments in pigs
The immunization and challenge experiments were per-
formed twice and the results obtained exhibited a good
concordance. In total, twenty-five pigs in experiment 1
and nineteen pigs in experiment 2, respectively, were ran-
domly allocated into 8 groups (Table 2) and sampled to
obtain preimmune sera. Animals in groups 1 to 6 were
intramuscularly injected with purified recombinant anti-
gens in oil adjuvant (antigen(s) diluted in 1.5 mL of PBS to
a final amount indicated in the text below plus 0.5 mL of
EMULSIGEN, MVP laboratories, Inc., USA) as follows:
G r o u p1 )1 2p i g s ,i m m u n i z e dw i t hr A p f A( 1 0 0μgp e r
dose); group 2) 3 pigs, injected with rApxIVA (100 μg per
dose); group 3) 3 pigs, immunized with rTbpB (100 μgp e r
dose); group 4) 3 pigs, immunized with a combination of
rApxIA, rApxIIA and rApxIIIA (50 μg each per dose);
group 5) 7 pigs, injected with a penta-antigen combination
of rApxIA, rApxIIA, rApxIIIA, rApxIVA and rTbpB pro-
teins (50 μg each per dose); group 6) 7 pigs, immunized
with a hexa-antigen vaccine including rApfA (100 μgp e r
dose) and rApxIA, rApxIIA, rApxIIIA, rApxIVA, rTbpB
(50 μg each per dose). Two weeks later all the groups were
revaccinated with the same dose of antigens. Seven pigs in
group 7 received PBS in oil adjuvant and 2 pigs in group 8
were left non-vaccinated. The post-vaccination sera from
all piglets were collected one day before challenge and the
levels of antibodies against the antigens were tested by
ELISA. Animals in groups 1 to 7 were intranasally chal-
lenged one month after the first immunization. Inocula
were applied using an intranasal probe and consisted of
the LD50 infectious dose of A. pleuropneumoniae serotype
9 strain (2 × 10
8CFU in 5 mL). Following challenge, piglets
were examined and scored daily over seven days using a 0
to 4 scale: 0, no signs of porcine pleuropneumonia; 1,
increased respiration rate, and/or sporadic coughing, and/
or occasional lying down, and/or mild apathy; 2, abdom-
inal respiration, and/or coughing, and/or lying down, and/
or apathy; 3, dyspnea, and/or regular coughing, and/or
lying down, and/or markedly depressed appearance, and/
or bloody discharge, and/or agony; 4, death. Moreover,
body temperature was taken daily. On day 7 post-chal-
lenge all surviving pigs were sacrificed and their lungs
were subjected to examination for lesions. These were
scored as previously described [49,68] with the follow-
ing modifications: 0, no pathological changes; 1, minor
pathological changes, 1-20% of the lobe affected; 2, lar-
ger damage of the lobe, 21-50% of the lobe affected; 3,
severe damage of the lobe, 51-100% of the lobe
affected. The left and right cranial, middle and caudal
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score was calculated for each animal. To check for
presence of the challenge bacteria, the cranial lobe of
each lung and lung portions exhibiting lesions were
replica printed on a blood agar plate (Columbia Blood
Agar Base, HIMEDIA, Mumbai, India) containing 6%
o fs h e e pd e f i b r i n a t e db l o o d .C o l o n i e so fA. pleuropneu-
moniae were grown for 48 h at 37°C in the hemolytic
zone of Staphylococcus aureus Cowan I (CCM 2352;
Veterinary Research Institute, Brno, Czech Republic).
After incubation, the presence of satellite colonies was
scored as suspect positive for A. pleuropneumoniae .
Suspect colonies were confirmed as A. pleuropneumo-
niae serotype 9 strain by the PCR method and the coa-
gulation test as previously described [69,70].
ELISA
Wells of the PolySorp ELISA plates (Nunc, Roskilde,
Denmark) were coated with 100 μL per well of particular
purified protein antigen in concentration of 32 ng/mL
(rApfA), 63 ng/mL (rApxIA), 63 ng/mL (rApxIIA), 32
ng/mL (rApxIIIA), 32 ng/mL (rApxIVA) and 750 ng/mL
(rTbpB), respectively. In addition, a mock extract of
E. coli BL21(lDE3), processed by the same chromato-
graphic procedure as the recombinant proteins, was also
used for coating, in order to control the reaction of sera
to any residual E. coli components within the protein
preparations. Plates were coated overnight at 4°C, washed
three times with 300 μL of PBS containing 0.05% Tween-
20 (Sigma-Aldrich, St. Louis, USA) (PBST) and blocked
for 1 h with 1% BSA (Sigma-Aldrich, St. Louis, USA) in
PBST. Serial dilutions of individual hyperimmune sera
were added and the plates were incubated for 1 h at
37°C. After rinsing with PBST, peroxidase-conjugated
rabbit anti-swine IgG (Amersham Biosciences, Piscat-
away, USA) was used at a 1:3 000 dilution and the plates
were incubated for 1 h at 37°C. After washing with PBST
and incubation with o-phenylenediamine peroxidase sub-
strate solution, the reactions were stopped with 2 M sul-
phuric acid and read at 492 nm using a Safire II
microplate reader (Tecan, Zürich, Switzerland). The cut-
off values for determination of anti-antigen (rApfA, rAp-
xIA, rApxIIA, rApxIIIA, rApxIVA or rTbpB) IgG
antibody titers were determined as the mean plus two
standard deviations from the test results of preimmune
sera at 1:100 dilution. The titers of antigen-specific anti-
bodies were then defined as the reciprocal of the last
dilution yielding an absorbance at 492 nm greater than
the cutoff value.
Statistical analysis
The values of clinical signs, body temperatures, lung lesion
scores and antibody titers were calculated from the data
obtained for particular animals included in a given
Table 2 Clinical score, lung lesion score and re-isolation of the challenge strain after immunization of pigs with
different vaccines, followed by heterologous intranasal challenge with A. pleuropneumoniae
Vaccine
1 Number of
pigs
2
Clinical
score
3
Body
temperature (°C)
4
Lung lesion
score
5
Re-isolation of the challenge
strain (%)
6
Surviving
pigs (%)
rApfA 12 1.7 ± 0.7
7 40.3 ± 0.5
7 1.3 ± 0.7
7 58
7 100
rApxIVA 3 2.6 ± 0.5 40.8 ± 0.4 1.8 ± 0.5 100 100
rTbpB 3 2.7 ± 0.5 40.9 ± 0.5 1.9 ± 0.7 100 100
rApxIA+rApxIIA+rApxIIIA 3 1.9 ± 0.7 40.5 ± 0.4 1.5 ± 0.6 100 100
rApxIA+rApxIIA+rApxIIIA+rApxIVA
+rTbpB
7 1.2 ± 0.5
7 39.9 ± 0.4
7 1.0 ± 0.6
7 86 100
rApfA+rApxIA+rApxIIA+rApxIIIA
+rApxIVA+rTbpB
7 0.3 ± 0.5
7,8 39.6 ± 0.5
7 0.3 ± 0.5
7,8 29
7 100
Control (PBS in oil adjuvant) 7 3.2 ± 0.7 41.2 ± 0.4 2.3 ± 0.7 100 57
Non-treated 2 0 39.1 ± 0.4 0 0 100
1Pigs were immunized with two doses of the indicated vaccines at two week intervals and challenged intranasally two weeks later with A. pleuropneumoniae
serotype 9 strain (2 × 10
8CFU).
2Two independent immunization and challenge experiments were performed. Total number of pigs per vaccine group is given.
3Following the challenge, pigs were examined for clinical signs of pleuropneumonia and scored every day for seven days using a 0 to 4 scale. Mean value for
each vaccination group calculated from two independent challenge experiments ± standard deviation is given.
4Following the challenge, body temperature was taken daily for seven days. Mean value for each vaccination group calculated from two independent challenge
experiments ± standard deviation is given.
5Upon death, or immediately upon sacrifice on day seven, all animals underwent necropsy and macroscopic inspection of lungs. The observed lung lesions were
scored using a 0 to 3 scale and mean value for each group calculated from two independent challenge experiments ± standard deviation is given.
6Percentages of pigs in each vaccination group from which the challenge strain of A. pleuropneumoniae was re-isolated.
7Statistically significant difference (P < 0.02) between the vaccine immunized group and the control group, each comprising at least 7 animals.
8Statistically significant difference (P < 0.02) between the combined hexa-antigen vaccine (rApfA, rApxIA to IVA and rTbpB) immunized group and the penta-
antigen vaccine (rApxIA to IVA and rTbpB) immunized group.
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tables thus represent mean values ± standard deviations.
To analyze the differences in various parameters among
the vaccination groups, the Student’s t -test was used on
groups comprising at least 7 animals and the threshold for
significance was set as P <0 . 0 2 .
Results
Cloning, expression and purification of recombinant
antigens
The genes coding for ApfA, ApxIA, ApxIIA, ApxIIIA,
ApxIVA and TbpB were amplified from genomic DNA of
A. pleuropneumoniae strains, cloned into an expression
vector and overexpressed in E. coli cells. Since the produc-
tion of the full-length ApfA protein was shown to be
highly toxic for E. coli [64], ApfA lacking the N-terminal
secretion signal and a predicted hydrophobic region (resi-
dues 1 to 35) was produced. The removal of the hydro-
phobic portion was expected to prevent the potential
aggregation of the recombinant ApfA and the observed
toxicity to E. coli cells [64]. All recombinant antigens were
purified close to homogeneity from inclusion bodies by an
affinity chromatography on Ni-NTA agarose. This proce-
dure yielded per liter of bacterial culture approximately
5m go fr A p f A ,4 0m go fr A p x I A ,r A p x I I Ao rr A p x I I I A ,
15 mg of rApxIVA and 50 mg of rTbpB, respectively.
Homogeneity of the final protein preparations was tested
by SDS-PAGE (Figure 1) and the identity of the recombi-
nant antigens was confirmed by MALDI-TOF mass spec-
trometry (data not shown).
Immunization with the ApfA antigen reduces clinical
signs of porcine pleuropneumonia and significantly
increases the potency of a multi-antigen vaccine
Prior to challenge, the pigs were randomly allocated into 8
groups and intramuscular immunization was performed
with rApfA, rApxIVA or rTbpB individually, or with a tri-
antigen combination of rApxIA to IIIA, or with a com-
bined penta-antigen vaccine containing rApxIA to IVA
and rTbpB, or with a hexa-antigen vaccine including
rApfA, rApxIA to IVA and rTbpB, or with PBS in oil adju-
vant, respectively (Table 2). Animals in the last group were
neither immunized nor challenged. Two independent
immunization and challenge experiments were performed.
The post-vaccination sera from all piglets were taken
one day before challenge and examined for anti-rApfA,
anti-rApxIA to IVA and anti-rTbpB antibody levels using
ELISA. As documented in Figure 2, the post-vaccination
sera taken from all animals of a given vaccination group
exhibited high titers (over 72 900) of antibodies against
each of the individual component of the vaccine, but did
not contain antibodies against an antigen that was not
included in the vaccine. As further documented in Figure
2, no significant levels of rApfA, rApxIA to IVA or
r T b p Bs p e c i f i ca n t i b o d i e sw e r ed e t e c t e di ns e r ao fa n i -
mals immunized with PBS in oil adjuvant or in sera of
non-treated animals. As a control, preimmune sera were
tested for the presence of anti-rApfA, anti-rApxIA to
IVA and anti-rTbpB antibodies and were found to be
negative (data not shown). Altogether, these results
demonstrated that the rApfA, rApxIA to IVA and rTbpB
116 
66 
45 
205 
(kDa) 
25 
14 
(kDa) 
66 
A B 
Figure 1 Purified recombinant ApfA, ApxIA, ApxIIA, ApxIIIA, ApxIVA and TbpB proteins. Recombinant proteins were purified on Ni-NTA
agarose columns, separated on a 15% (rApfA) (A) or 7.5% (all other proteins) (B) polyacrylamide gel and stained with Coomassie Blue.
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Figure 2 Titration of porcine post-vaccination sera. Pigs were immunized with two doses of the indicated vaccines at two week intervals
and the post-vaccination sera from all piglets were taken one day before challenge and examined for the anti-rApfA (A), anti-rApxIA (B), anti-
rApxIIA (C), anti-rApxIIIA (D), anti-rApxIVA (E) and anti-rTbpB (F) antibody levels using ELISA. Each point represents an average value calculated
from results obtained for titration of sera taken from all pigs included in the given vaccination group ± standard deviation.
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serum antibodies.
The protective potency of the vaccines was tested in
heterologous challenge experiments using an infectious
dose of 2 × 10
8CFU of A. pleuropneumoniae serotype 9
strain that was applied via the intranasal route one
month after the first immunization. In the control group
of animals that received PBS in oil adjuvant, all pigs suf-
fered from severe cough, dyspnea, apathy and fever fluc-
tuating between 40.8-41.6°C within seven days following
the challenge with A. pleuropneumoniae serotype 9 strain
(Table 2). Two out of seven pigs died within 24 h after
the challenge and one animal was found dead on the sec-
ond day after inoculation, while the remaining pigs sur-
vived until the end of the study, despite severe clinical
signs of porcine pleuropneumonia. Upon necropsy, all
pigs in this group showed lung lesions characterized by a
hemorrhagic necrotizing pneumonia and fibrinous pleur-
itis typical of A. pleuropneumoniae infection with the
mean lung lesion score 2.3 ± 0.7 out of 3 (Table 2). The
challenge strain was re-isolated from the lungs of all pigs,
confirming the etiology of the lesions (Table 2). These
results demonstrated that the challenge with the hetero-
logous A. pleuropneumoniae serotype 9 strain caused
typical signs of severe porcine pleuropneumonia.
In contrast to animals that received only PBS in oil adju-
vant, the pigs vaccinated with rApfA showed considerably
milder clinical signs of porcine pleuropneumonia (Table
2). The animals suffered from coughing, increased respira-
tion rate and mild apathy for seven days after the chal-
lenge and fever up to 40.8°C. Corresponding to milder
clinical signs of pleuropneumonia, also the mean lung
lesion score was significantly lower in animals immunized
with rApfA (1.3 ± 0.7, P < 0.02), when compared to the
control (2.3 ± 0.7) (Table 2). The challenge strain was re-
isolated from the lungs of seven out of twelve animals
(Table 2).
Immunization with rApxIVA or rTbpB alone or with
the tri-antigen combination of rApxIA to IIIA, respec-
tively, did not protect the challenged animals against
development of clinical signs of the disease, however,
none of the pigs died within seven days following the
challenge (Table 2). Upon challenge, the animals immu-
nized with rApxIVA or rTbpB alone suffered mainly
from cough, abdominal respiration, dyspnea, apathy and
fever up to 41.4°C. Upon necropsy, a massive destruction
of the lung tissue was observed (Table 2). On the con-
trary, the pigs vaccinated with the tri-antigen combina-
tion of rApxIA to IIIA showed milder clinical signs of
porcine pleuropneumonia and lower mean lung lesion
score than the animals vaccinated with rApxIVA or
rTbpB alone (Table 2). The challenge strain was recov-
ered from the lungs of all pigs vaccinated with rApxIVA
or rTbpB alone or with the tri-antigen combination,
respectively (Table 2).
All these data demonstrate that rApfA alone provided
a partial protection against infection with A. pleuropneu-
moniae that was higher than the protection conferred by
the immunization with rApxIVA or rTbpB alone and
similar to the protection after vaccination with the tri-
antigen combination of rApxIA, rApxIIA and rApxIIIA.
When the purified rApxIA to IVA and rTbpB proteins
were combined in a penta-antigen vaccine and used for
immunization, a high level of protection against the
challenge with A. pleuropneumoniae serotype 9 strain
was observed (Table 2). Pigs mainly suffered from
increased respiration rate, coughing, occasional lying
down and mild fever not exceeding 40.3°C. The
observed clinical signs had a tendency to diminish over
the seven day period after the challenge. The mean lung
lesion score was significantly lower in animals immu-
nized with the combined penta-antigen vaccine (1.0 ±
0.6, P < 0.02), when compared to the control group
( 2 . 3±0 . 7 )( T a b l e2 ) .T h ec h a l l e n g es t r a i nw a sr e - i s o -
lated from the lungs of six out of seven pigs included in
this experimental group (Table 2). These data indicate
that the penta-antigen vaccine provided high level of
protection against acute disease upon challenge with
A. pleuropneumoniae .
When this penta-antigen vaccine was supplemented
with the purified rApfA and used for immunization, the
combined hexa-antigen vaccine containing rApfA, rApxIA
to IVA and rTbpB, respectively, conferred on animals a
high level of protection against all clinical signs accompa-
nying acute infection (Table 2). Pigs showed only sporadic
coughing and occasional lying down for the first three
days and presented mild fever about 40.1°C during the
first two days after the challenge. After the period of three
days, none of the animals showed any clinical signs of the
disease or fever. Following necropsy, none or only minor
pathological changes were observed in the lungs of these
animals and the mean lung lesion score was 0.3 ± 0.5
(Table 2), which was fully in line with the absence of signs.
The challenge strain was isolated from the lungs of only
two out of the seven challenged animals (Table 2). These
results demonstrate that rApfA further improved the vac-
cine potency of the currently used antigens and that the
immunization with the combined hexa-antigen vaccine
consisting of rApfA, rApxIA to IVA and rTbpB enabled a
high level of protection of pigs against pleuropneumonia.
Moreover, rApfA used alone or in combination with other
antigens significantly decreased the number of animals
colonized by the heterologous challenge strain of A. pleur-
opneumoniae . Hence, ApfA should be included in a new
generation of subunit vaccines against porcine pleurop-
neumonia, providing not only a complete protection of
Sadilkova et al. Veterinary Research 2012, 43:2
http://www.veterinaryresearch.org/content/43/1/2
Page 8 of 12pigs against the clinical signs of the acute disease, but also
limiting lung colonization by A. pleuropneumoniae .
Discussion
To develop more effective subunit vaccines against por-
cine pleuropneumonia, the identification, production and
testing of novel A. pleuropneumoniae protein antigens are
the objectives of current research. We show here that the
type IV fimbrial subunit protein ApfA should be consid-
ered as a promising vaccine candidate.
We demonstrate that vaccination of pigs with the
recombinant ApfA protein alone provided limited protec-
tion against heterologous challenge with A. pleuropneumo-
niae . This result was in agreement with previous reports
showing that single antigen vaccines offer only partial or
no protection against pleuropneumonia. For instance,
when ApxIIA and TbpB proteins expressed in E. coli were
used for vaccination separately, all pigs developed a strong
humoral immune response and upon challenge with a
homologous A. pleuropneumoniae serotype 7 strain, all
immunized animals were less affected by the pleuropneu-
monia and demonstrated significantly lower mortality
than the controls [53]. However, protection was serotype-
specific, since no cross-protection was detected, when the
animals were challenged with an A. pleuropneumoniae ser-
otype 1 strain [53]. Recently, the N-terminal portion of
ApxIVA produced in E. coli was used for vaccination and
the challenged pigs showed similar severe respiratory signs
and severe lung lesions as the animals in the control
group, despite high antibody titers against the N-terminus
of ApxIVA [49]. We obtained similar results showing that
the vaccination of pigs with full-length rApxIVA or rTbpB
alone protected animals against death upon heterologous
challenge with A. pleuropneumoniae serotype 9 strain, but
did not protect them against development of clinical signs
of the disease and massive destruction of the lung tissue,
despite high titers of specific antibodies. In contrast, the
pigs immunized with the recombinant ApfA alone showed
milder clinical signs of porcine pleuropneumonia and
reduced destruction of the lung tissue than the animals
vaccinated with rApxIVA or rTbpB alone.
Since single antigens often provide only limited protec-
tion against porcine pleuropneumonia, multi-antigen sub-
unit vaccines were used for immunization. For instance,
pigs receiving a mixture of the recombinant ApxIIA and
TbpB proteins had a tendency to recover faster than ani-
mals that were vaccinated with only one antigen [53].
Similarly, the N-terminal portion of ApxIVA improved
protective immunity conferred by the subunit vaccine con-
taining recombinant ApxIA, ApxIIA, ApxIIIA and the 42-
kDa outer membrane protein [49]. Therefore, we also
tested whether recombinant ApfA would improve protec-
tion upon its addition to a multi-antigen subunit vaccine.
Our data demonstrate that the immunization of pigs with
the combined hexa-antigen vaccine consisting of rApfA,
rApxIA to IVA and rTbpB provided protective immunity
against pleuropneumonia that was significantly higher
than that acquired upon vaccination with rApfA, rApxIVA
or rTbpB alone, with the tri-antigen combination of rAp-
xIA, rApxIIA and rApxIIIA or even with the penta-antigen
subunit vaccine composed of rApxIA to IVA and rTbpB.
Thus, rApfA improved the vaccination potential of cur-
rently used antigens. Moreover, immunization of pigs with
the combined hexa-antigen vaccine provided almost com-
plete protection of animals against the heterologous chal-
lenge with A. pleuropneumoniae serotype 9 strain.
Recently, the contribution of recombinant ApfA to the
protective immunity of a subunit vaccine comprising rAp-
xIA, rApxIIA, rApxIIIA and rOMP was tested in mice [71].
It has been shown that the antibody titers against rApxIA,
rApxIIA, rApxIIIA and rOMP were significantly lower in
sera of mice immunized with the vaccine containing
rApfA, rApxIA to IIIA and rOMP than the titers in sera of
mice immunized with the vaccine comprising only rApxIA
to IIIA and rOMP. In agreement, upon challenge with
A. pleuropneumoniae, mice immunized with the vaccine
containing rApfA, rApxIA to IIIA and rOMP had the
lower survival rate and more severe lung lesions than the
animals immunized with the vaccine lacking rApfA. Thus,
it has been suggested that vaccination with rApfA may
impair immunity of mice [71], similarly as described for
the outer membrane protein PalA of A. pleuropneumoniae
in pigs [68]. Our immunization and challenge experiments
in pigs, however, do not support the observation achieved
with rApfA in mice. As documented in Figure 2, we clearly
show that the post-vaccination sera of pigs immunized
with the hexa-antigen vaccine containing rApfA, rApxIA
to IVA and rTbpB exhibited higher or comparable levels of
rApxIA, rApxIIA or rApxIIIA specific antibodies than the
sera of animals immunized with the penta-antigen vaccine
comprising only rApxIA to IVA and rTbpB. In addition,
the hexa-antigen vaccine conferred on pigs a significantly
better protection against pleuropneumonia than did the
penta-antigen vaccine lacking rApfA (Table 2).
Type IV fimbriae are known to play a key role in viru-
lence of many species of Gram-negative bacteria and
therefore type IV fimbrial subunit proteins have been
tested as subunit vaccines for the prevention of several dis-
eases. For instance, a highly purified fimbriae prepared
from cells of Dichelobacter nodosus provided a high level
of protection against ovine foot-rot upon homologous
challenge and lower levels of protection against challenge
with strains of different serogroups [72]. Similarly, type IV
fimbriae isolated and purified from different strains of
Moraxella bovis effectively protected cattle against experi-
mentally induced infectious bovine keratoconjunctivitis
upon homologous challenge, but provided only partial
protection against challenge with a strain of different
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pilin gene inversion enabling bacterial escape from protec-
tive immunity was suggested to occur in response to the
presence of pilin-specific antibodies upon vaccination with
purified fimbriae of M. bovis [74]. The antigenic variation
of the pilin subunit has also been an important obstacle to
the development of an effective pilus-based vaccine for
Neisseria gonorrhoeae [75].
We demonstrate here that despite high antibody titers
against rApfA, vaccination of pigs with rApfA alone pro-
vided only partial protection against heterologous chal-
lenge with A. pleuropneumoniae . However, the apfA
alleles were found to be highly conserved and present in a
single copy in the genomes of different A. pleuropneumo-
niae serotype strains [18]. Therefore, the observed partial
protection of immunized animals against pleuropneumo-
nia was most probably not due to the low level of the
ApfA sequence homology or the pilin antigenic variation
in the challenge strain. A more plausible explanation is
that some additional components to type IV fimbriae are
involved in adherence of A. pleuropneumoniae to alveolar
epithelial cells, which is an important initial step in the
pathogenesis of porcine pleuropneumoniae [20,76].
Indeed, A. pleuropneumoniae was shown to bind to phos-
phatidylethanolamine of the host cells through O-antigen
of its cell-wall lipopolysaccharides [77]. Moreover, a 55-
kDa outer membrane protein (OMP) was shown to play a
role in the adherence of A. pleuropneumoniae to alveolar
epithelial cells in culture [78]. Thus, a multiple-step bind-
ing process has been suggested, in which A. pleuropneu-
moniae first uses low-affinity binding between O-antigen
and phospholipids or short glycolipids and then relies on
the core oligosaccharide of LPS and/or surface proteins,
such as 55-kDa OMP and type IV fimbriae, to interact
more avidly with other larger lipidic and/or proteinaceous
receptors on host cells [77]. The use of multiple parallel
adhesion mechanisms by A. pleuropneumoniae and invol-
vement of additional virulence factors would, hence, pro-
vide a likely explanation for the observed only partial
protective efficacy of the vaccine based solely on ApfA,
which was not able to completely prevent the colonization
of the lungs of pigs by the challenge strain of A. pleurop-
neumoniae . Conversely, the reduction of the number of
pigs colonized by the challenge strain up to 29% upon
immunization with the ApfA-based vaccines suggests that
ApfA-specific antibodies might markedly inhibit the pilus-
mediated binding of A. pleuropneumoniae to host cells,
despite the existence of other adherence mechanisms.
In conclusion, our results demonstrate that immuniza-
tion of pigs with the type IV fimbrial subunit protein
ApfA induced specific serum antibody response that
reduced clinical signs of the acute disease upon hetero-
logous challenge with A. pleuropneumoniae and
significantly increased the potency of the currently used
protective antigens. Thus, ApfA could be a candidate to
be included in a next generation of subunit vaccines
against porcine pleuropneumonia.
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